Use of the polymerase chain reaction in the diagnosis of herpes simplex encephalitis: a decision analysis model.
OBJECTIVE
To evaluate the utility of an assay based on a polymerase chain reaction (PCR) of cerebrospinal fluid in the management of patients with suspected herpes simplex encephalitis.


METHODS
A decision model was constructed and used to compare a PCR-based approach with empiric therapy. Inputs required by the model included the sensitivity (96%) and specificity (99%) of PCR (derived from review of the literature), the prevalence of herpes simplex encephalitis (5%, based on the actual prevalence at Barnes Hospital among patients treated empirically with acyclovir), the outcomes for patients with and without herpes simplex encephalitis (derived from clinical studies of the Collaborative Antiviral Study Group and the actual experience at Barnes Hospital), and the average duration of empiric acyclovir therapy for patients with possible herpes simplex encephalitis (5.3 days based on actual experience at Barnes Hospital).


RESULTS
Using these input values, the decision model predicted better outcomes with empiric therapy. However, low rates of inappropriate discontinuation of empiric therapy in patients with herpes simplex encephalitis or improved diagnosis and outcome resulting from a negative PCR assay result in patients without herpes simplex encephalitis led to better outcomes with the PCR-based approach. The PCR-based approach was associated with 9.2 fewer doses of acyclovir per patient.


CONCLUSIONS
Based on the decision model using conservative assumptions, a PCR-based approach can yield better outcomes and reduced acyclovir use compared with empiric therapy.
Tebas
P
P
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Nease
R F
RF
Storch
G A
GA
D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001499:Bayes Theorem; D003661:Decision Support Techniques; D003937:Diagnosis, Differential; D018792:Encephalitis, Viral / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D006561:Herpes Simplex / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D016133:Polymerase Chain Reaction; D015995:Prevalence; D012680:Sensitivity and Specificity; D018139:Simplexvirus / Q000235:genetics*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000212:Acyclovir